131 filings
Page 6 of 7
8-K
da3i vm8vevt8t2pdokj
21 Sep 15
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
8-K
e3c tse8rrp5fc
16 Sep 15
Other Events
12:00am
8-K
f1lkr3
2 Sep 15
Intra-cellular Therapies Announces Publication of Positive Phase 2 Schizophrenia Study In the Journalbiological Psychiatry
12:00am
8-K
cxwwezue67
5 Aug 15
Intra-Cellular Therapies Reports Second Quarter 2015 Financial Results and Provides Corporate Update
12:00am
8-K
10qh6p0wr
22 Jul 15
Other Events
12:00am
8-K
d6cjy
24 Jun 15
Intra-Cellular Therapies Reports Initiation of Randomization for ITI-007-302 Phase 3 Trial in Schizophrenia
12:00am
8-K
nn3xneb
18 Jun 15
Departure of Directors or Certain Officers
12:00am
8-K
reyf29au5y0l4gfttt
15 Jun 15
Other Events
12:00am
8-K
i7pbdpspam
28 May 15
Entry into a Material Definitive Agreement
12:00am
8-K
2j7fo7bu
19 May 15
Other Events
12:00am
8-K
nmygxatoq
30 Apr 15
Intra-Cellular Therapies Reports First Quarter 2015 Financial Results and Provides
12:00am
8-K
mkho7cc3i4 ea6kv52
31 Mar 15
Intra-Cellular Therapies Presents the ITI-007 Clinical Development Program at the 15th International Congress on Schizophrenia Research
12:00am
8-K
ly5e 7kbb67h2zwirs7s
12 Mar 15
Intra-Cellular Therapies Announces Closing of $130 Million Public Offering Including
12:00am
8-K
o1lx0mdw0ey2s ubst
6 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
sjewpamq
4 Mar 15
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
12:00am
8-K
z2wbdm04rxri
3 Nov 14
Results of Operations and Financial Condition
12:00am
8-K
hokry5sjesy5keg4ranx
12 Aug 14
Company announces successful End-of Phase 2 meeting with the FDA and Phase 3 plans for ITI-007 for schizophrenia
12:00am
8-K
58ufeo3
3 Jul 14
Submission of Matters to a Vote of Security Holders
12:00am
8-K
mcd4nos1dq
6 May 14
Other Events
12:00am
8-K
s7xfhdiv49i3 6bjy8
5 May 14
Intra-Cellular Therapies Reports First Quarter 2014 Financial Results
12:00am